AGAP3 as A Potential Drug Target for Alzheimer's (G116988)

Target Name: AGAP3

NCBI ID: G116988

AGAP3

AGAP3 as A Potential Drug Target for Alzheimer's

AGAP3 (Alzheimer's disease-associated protein 3) is a protein that is expressed in the brain and has been linked to the development and progression of Alzheimer's disease. It is a small protein that is made by the brain and has been shown to be involved in the formation of beta-amyloid plaques, which are a hallmark of Alzheimer's disease.

Recent studies have suggested that AGAP3 may be a drug target or biomarker for the treatment of Alzheimer's disease. This is because AGAP3 has been shown to be involved in the formation of beta-amyloid plaques, which are a major cause of the development and progression of Alzheimer's disease. By targeting AGAP3, researchers may be able to reduce the formation of beta-amyloid plaques and potentially slow down or even reverse the progression of Alzheimer's disease.

One way that AGAP3 may be targeted as a drug is through its role in the formation of beta-amyloid plaques. Researchers have shown that AGAP3 is involved in the formation of beta-amyloid plaques by helping to transport the amino acid LDL (low-density lipoprotein) to the brain. When LDL is introduced to the brain, it can react with a protein called APP (amyloid precursor protein) to form beta-amyloid plaques.

In addition to its role in the formation of beta-amyloid plaques, AGAP3 has also been shown to be involved in the regulation of the immune response. This is important because the immune response is thought to play a role in the development and progression of Alzheimer's disease.

Research has also suggested that AGAP3 may be involved in the regulation of the blood-brain barrier. The blood-brain barrier is a barrier that separates the brain from the blood and helps to protect it from harmful substances. AGAP3 has been shown to be involved in the regulation of the blood-brain barrier, which may be important for the treatment of Alzheimer's disease.

Overall, AGAP3 is a protein that has been linked to the development and progression of Alzheimer's disease. Recent studies have suggested that AGAP3 may be a drug target or biomarker for the treatment of Alzheimer's disease, due to its involvement in the formation of beta-amyloid plaques and its role in the regulation of the immune response and blood-brain barrier. Further research is needed to fully understand the potential role of AGAP3 in the treatment of Alzheimer's disease.

Protein Name: ArfGAP With GTPase Domain, Ankyrin Repeat And PH Domain 3

Functions: GTPase-activating protein for the ADP ribosylation factor family (Potential). GTPase which may be involved in the degradation of expanded polyglutamine proteins through the ubiquitin-proteasome pathway

The "AGAP3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AGAP3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets